Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience.

This letter to the editor discusses the use of tralokinumab, a selective inhibitor of interleukin (IL)-13, for the treatment of moderate-to-severe atopic dermatitis (AD). The authors retrospectively analyzed data from 10 patients who were treated with tralokinumab for at least 16 weeks. They found that tralokinumab significantly improved subjective symptoms and quality of life in these patients, with a reduction in itch and improvement in clinical scores. The treatment was generally well-tolerated, with no significant safety concerns. The authors conclude that tralokinumab shows promise for the treatment of AD in real-world patients. [Extracted from the article]